Related Experiment Video
Updated: Jun 12, 2025

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
Published on: September 21, 2017
Stapled Peptides as Inhibitors of mRNA Deadenylation
Sunit Pal1, Ilja Gordijenko1, Stefan Schmeing1
1Chemical Genomics Centre, Max Planck Institute of Molecular Physiology, Otto-Hahn-Strasse 11, 44227, Dortmund, Germany.
Abstract:
Therapeutic intervention targeting mRNA typically aims at reducing the levels of disease-causing sequences. Achieving the opposite effect of blocking the destruction of beneficial mRNA remains underexplored. The degradation of mRNA starts with the removal of poly(A) tails, reducing their stability and translational activity, which is mainly regulated by the CCR4-NOT complex. The subunit NOT9 binds various RNA binding proteins, that recruit mRNA in a sequence-specific manner to the CCR4-NOT complex to promote their deadenylation. These RNA binding proteins interact with NOT9 through a helical NOT9 binding motif, which we used as a starting point for development of the hydrocarbon stapled peptide NIP-2. The peptide (KD=60.4 nM) was able to inhibit RNA-binding (IC50=333 nM) as well as the deadenylation activity of the CCR4-NOT complex in vitro while being cell-permeable (cell-permeability EC50=2.44 μM). A co-crystal structure of NIP-2 bound to NOT9 allowed further optimization of the peptide through point mutation leading to NIP-2-H27A-N3 (KD=122 nM) with high cell permeability (cell-permeability EC50=0.34 μM). The optimized peptide was able to inhibit deadenylation of target mRNAs when used in HeLa cells at a concentration of 100 μM, demonstrating the feasibility of increasing mRNA stability.
Insights
Researchers developed a novel peptide, NIP-2, to inhibit messenger RNA (mRNA) degradation by targeting the CCR4-NOT complex. This approach stabilizes beneficial mRNA, offering a new therapeutic strategy to increase mRNA levels.
Area of Science:
- Molecular Biology
- Biochemistry
- Drug Discovery
Background:
- Therapeutic strategies often focus on reducing disease-causing mRNA.
- Stabilizing beneficial mRNA by preventing its degradation is an underexplored area.
- mRNA degradation, initiated by poly(A) tail removal, is regulated by the CCR4-NOT complex.
Purpose of the Study:
- To explore methods for blocking the destruction of beneficial mRNA.
- To develop a peptide-based inhibitor targeting the CCR4-NOT complex's deadenylation activity.
- To investigate the potential of stabilizing mRNA for therapeutic benefit.
Main Methods:
- Identified the NOT9 binding motif in the CCR4-NOT complex as a target.
- Designed and synthesized hydrocarbon stapled peptides, starting with NIP-2.
- Utilized co-crystallography for peptide optimization and in vitro/cell-based assays to assess inhibition and cell permeability.
Main Results:
- Developed NIP-2 peptide with nanomolar affinity for NOT9 and potent inhibition of RNA binding and deadenylation in vitro.
- Demonstrated cell permeability of NIP-2 (EC50 = 2.44 μM).
- Optimized peptide NIP-2-H27A-N3 showed improved affinity and significantly enhanced cell permeability (EC50 = 0.34 μM), inhibiting mRNA deadenylation in HeLa cells.
Conclusions:
- Peptide-based inhibition of the CCR4-NOT complex is feasible.
- The developed peptides can effectively inhibit mRNA deadenylation and increase mRNA stability.
- This strategy presents a novel therapeutic avenue for conditions requiring increased levels of specific beneficial mRNAs.
Related Concept Videos
mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Nuclear Export of mRNA
RNA Stability
Experimental RNAi
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...

